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(NMDT). Our aim was to obtain a national picture of CM referrals, to assess referral
volume and quality and factors affecting NMDT decision-making.
Methods:  Prospective multicenter cohort study including all adult patients referred to
NMDT with ≥1CM. Data was collected in neurosurgical units from 11/2017 to 02/2018.
Demographics, primary disease, Karnofsky Performance Status (KPS), imaging and
treatment recommendation were entered into an online database.
Results:  1048 patients were analyzed from 24 neurosurgical units. Median age was
65[range 21-93] years with a median number of 3[range 1-17] referrals per NMDT. The
most common primary malignancies were lung (36.5%, n=383), breast (18.4%, n=193)
and melanoma (12.0%, n=126). 51.6% (n=541) of the referrals were for solitary
metastasis, and resulted in specialist intervention being offered in 67.5% (n=365).
38.2% (n=186) of patients being referred with multiple CMs were offered specialist
treatment. NMDT decision-making was associated with number of CMs, age, KPS,
primary disease status and extent of extracranial disease (univariate logistic
regression, p<0.0001) as well as sentinel location and tumor histology (p<0.05). A
delay in reaching an NMDT decision was identified in 18.6% (n=195).
Conclusions:  This study demonstrates a changing landscape of metastasis
management in the UK and Ireland, including a trend away from adjuvant whole brain
radiotherapy and specialist intervention being offered to a significant proportion of
patients with multiple CMs. Poor quality or incomplete referrals cause delay in NMDT
decision-making.
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Department of Neurosurgery, King's College Hospital 
Denmark Hill, London SE5 9RS, UK 
Susan Chang MD 
Editor-in-Chief Neuro-Oncology Practice 
Oxford Academic Oxford Journal 
London, 14th August 2019 
 
Dear Editor, 
 
Please find enclosed the revised manuscript entitled “Management Evaluation of Metastasis 
in the Brain (MEMBRAIN) – A United Kingdom & Ireland prospective, multicenter 
observational study” (Ref.:  Ms. No. NOP-D-19-00065) by Josephine Jung, Jignesh Tailor, 
Emma Dalton, Laurence J Glancz, Joy Roach, Rasheed Zakaria, Simon Lammy, Aswin 
Chari, Karol P Budohoski, Laurent J Livermore, Kenny Yu, Michael D Jenkinson, Paul M 
Brennan, Lucy Brazil, Catey Bunce, Elli Bourmpaki, Keyoumars Ashkan and Francesco 
Vergani that we submit for possible publication in Neuro-Oncology Practice. 
This study was conducted using the British Neurosurgical Trainee Research Collaborative 
which is a member organisation of the UK Neurosurgical Research Network supported by the 
Royal College of Surgeons of England and the Society of British Neurological Surgeons.  
 
In this study we investigated the management of brain metastases referrals to the neuro-
oncology multi-disciplinary team in 24 neurosurgical units in the United Kingdom and 
Ireland over the period of 4 months. We can show in our manuscript that there is a delay in 
decision-making in approximately ~20% of patients. Specialist intervention was offered to 
67.5% of patients with single CM and 38.2% of patients with multiple CMs, hence 
confirming a national change in culture of referral and treatment patterns. We believe that our 
findings contribute greatly to the knowledge within the scientific community. 
 
All authors have agreed with the manuscript submission and approved the final version of 
this manuscript. None of the authors have any conflicts of interest regarding the submitted 
article. We have closely followed the guidelines for authors. The content of this manuscript 
has not been published elsewhere in any form except as described here. 
 
Cover Letter
I, Josephine Jung, certify that this manuscript is a unique submission and is not being 
considered for publication, in part or in full, with any other source in any medium. 
Each of the above stated authors has participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. None of the authors have any financial 
disclosure or any conflict of interest. We have adhered to the local ethical guidelines of the 
hospital for publication of original articles. 
 
Correspondence regarding this manuscript should be sent to Josephine Jung at the address 
shown in this letter or via E-mail to Josephine.Jung@nhs.net. 
 
Thank you for the privilege of submitting our manuscript to your journal. 
 
Sincerely yours, 
 
Josephine Jung 
 
 
September 4, 2019 
 
 
Re: Resubmission of manuscript Management Evaluation of Metastasis in the Brain (MEMBRAIN) – A 
United Kingdom & Ireland prospective, multicenter observational study, Ms. Ref. No.: NOP-D-19-
00065 
 
 
The Editors 
Neuro-Oncology Practice 
 
 
Dear Editors: 
 
Thank you for the opportunity to revise our manuscript, Management Evaluation of Metastasis in 
the Brain (MEMBRAIN) – A United Kingdom & Ireland prospective, multicenter observational study. 
We appreciate the careful review and constructive suggestions of the Reviewers. Considerable 
changes have been made to the paper, in accordance with the improvements suggested by the 
reviewers. It is our belief that the manuscript has substantially improved after making the suggested 
edits, so to meet the high standard required for publication in Neuro-Oncology Practice. 
 
Please find below the reviewers’ comments with our responses in italics, including how and where 
the text was modified in the clean version of the manuscript. Changes made in the manuscript are 
marked using the ‘track changes’ mode. The revision has been developed in consultation with all co-
authors, and each author has given approval to the final form of this revision. 
 
 
 
Thank you for your consideration. 
 
Yours sincerely, 
 
Josephine Jung, MD PhD 
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Reviewers;Revision letter_04092019.docx
 
 
REVIEWER #1: 
 
This is an interesting study describing management decisions for over 1000 patients with cerebral 
metastases in the UK. 
 
The results would be of great interest for comparison to other populations of patients with cerebral 
metastases. However, it is not at all clear that the results are referable to international patient 
populations, particularly in the US and possibly Europe and Asia. 
 
1. The study emphasizes the number of patients recommended for "specialist" treatment, which 
includes surgery or radiosurgery, but apparently does not include whole brain radiation. Such a 
distinction would have to be considered a feature of the UK health system approach to management 
of these patients. At the very least, definition of the criteria for "specialist" versus "non-specialist" 
management needs to be provided. 
 
Thank you for this valuable comment. The difference between “Specialist” vs. “Non-Specialist” 
treatment is that surgery or SRS are provided by dedicated neuro-oncology centers, which are usually 
located in large tertiary referral hospitals whereas whole brain radiotherapy is administered by 
Clinical Oncologists working in general oncology departments and therefore it is more widely and 
readily available than SRS. This is a feature of the United Kingdom National Health Service but also 
similar in most European countries. We acknowledge that this may not be obvious to the general 
reader. This section has been expanded further in the methods section of our manuscript. 
 
Lines 87-91 
“[…] treatment recommendation (“specialist” interventions as recommended by a dedicated 
Neuro-Oncology center (Neuro-Oncologist, Neurosurgeon) located in a large tertiary referral unit: 
surgical resection, cerebrospinal fluid (CSF) diversion, SRS, cavity SRS; “non-specialist” treatment 
as provided by a General Oncologist: chemotherapy, immunotherapy, WBRT, local fractionated 
radiotherapy, best supportive care, other) […].” 
 
2. A remarkable feature in the results reported is the high number of patients treated with "Surgical 
Resection alone". The very fact that such a high number of patients are managed with surgical 
resection ALONE indicates that the study population is not easily compared to patients in the US, 
where the majority of patients are offered SRS or RT following surgery, even for solitary metastases. 
 
 
Thank you for allowing us to clarify this point further. Current NICE (The National Institute for Health 
and Care Excellence) guidelines support SRS to the resection cavity after initial surgery if there was 
any residual tumor and if that is documented by post-operative MRI. If complete resection has taken 
place, NICE recommends close follow up MRI observation only. That is why usually the initial MDT 
recommendation is for surgery alone - but a number of patients will receive SRS after surgery but this 
may not have been captured in this study. A small section has been added in the discussion section to 
reflect this fact. 
 
The authors agree that the results reflect the UK population, where probably less patients overall get 
the combination of surgery + cavity SRS as compared to the US. However, we think that it is relevant 
to report different practice and treatment modalities in an international journal such as Neuro-
Oncology Practice. While the authors recognize that there is some clinical evidence of better local 
control and less neuro-cognitive toxicity with cavity SRS (Choi CY et al., Int J Radiat Oncol Biol Phys. 
(2012), doi: 10.1016/j.ijrobp.2011.12.009; Roberge D et al., Int J Radiat Oncol Biol Phys. (2012, doi: 
10.1016/j.ijrobp.2011.09.032; Soltys SG et al., Int J Radiat Oncol Biol Phys. (2008), doi: 
10.1016/j.ijrobp.2007.06.068), however there is still a lack of long-term data available (Soffietti R et 
al., Neuro-Oncology (2016), doi: 10.1093/neuonc/nov286). 
 
Lines 328-331 
“Furthermore, while SRS to the resection cavity is supported by NICE if there is residual disease 
documented by post-operative MRI, this may not be recommended at the initial NMDT. 
Therefore, a proportion of patients will have had cavity SRS without this being captured in this 
study.” 
 
3. The authors indicate that the study shows major changes in management patterns for patients 
with cerebral metastases, but doesn't actually provide the basis for such assertions. Are they 
comparing their results to some historical data? 
 
Thank you for this comment. When comparing the data collected in this study to our previously 
collected and published data (Loh et al., BJNS, 2018) analyzing 1640 patients from 2013-15, we found 
that in our current study WBRT/Oncology treatment is recommended less often (39% in Loh et al. vs. 
20% in this current study). Furthermore, in Loh et al. approximately half of patients with solitary 
metastasis were recommended either SRS or surgery compared to only about 10% of patients with 
multiple metastases (p<0.001). In our current study the percentage of patients with multiple 
 
 
metastases having surgery or SRS recommended is higher (38%). A paragraph has been added to the 
discussion to emphasize this point. 
 
Lines 227-229 
“The change in practice reflects the fact that 38.2% (n=186) of the patients referred with multiple 
metastases were recommended specialist intervention, as compared to ~10% of patients in a 
single-center series of 1640 patients from 2013-2015.” (Loh et al., BJNS, 2018) 
 
4. It seems that the study results would be better submitted to a journal based in the UK, since the 
data would be of much greater value to UK-based neuro-oncologists and investigators. 
 
As mentioned above, we do believe that reporting different management and recommended 
treatment modalities in different countries should be of interest to an international journal like 
Neuro-Oncology Practice. Additionally, we would welcome a debate concerning how other 
international practices differ (including an invitation to letters in response) which can then in turn 
potentially inform and change UK practice. 
  
 
 
REVIEWER #2: 
 
I have minor concerns: 
 
1. Please detail who is required to form a « neuro-oncology multidisciplinary team ». It may vary 
between countries. 
 
Thank you for this comment. The neuro-oncology multidisciplinary team in the UK is comprised of: 
Consultant Neurosurgeon, Neurologist, Neuro-Radiologist, Neuro-Oncologist, Neuro-
Histopathologist; Neuro-Oncology Clinical Nurse Specialists; Occupational and Speech & Language 
Therapists; Physiotherapists; MDT coordinator and Neuro-Psychologist (where available). A 
paragraph detailing this has been added to the manuscript. 
 
Lines 69-73 
“The NMDT was composed of a variety of team members including but not limited to: Consultant 
Neurosurgeon, Neurologist, Neuro-Radiologist, Neuro-Oncologist, Neuropathologist; Neuro-
Oncology Clinical Nurse Specialists; Occupational and Speech and Language Therapists, 
Physiotherapists, coordinators and a Neuro-Psychologist, where available.” 
 
2. Several parameters are entered into a electronic Case Report Form. Are they the same for the 
study and for the clinical practice ? In other words, what are the parameters required to submit a 
case to the neuro-oncology multidisciplinary team ? 
 
Thank you for this interesting question and valuable point. The parameters described in this study for 
the electronic Case Report Form were used exclusively for the purpose of this study The criteria for 
submission to the neuro-oncology multidisciplinary team vary amongst individual centers which is 
why we proposed the use of a “uniform national proforma” for all neuro-oncology multidisciplinary 
teams in the UK in our discussion (lines 279-383). 
 
3. In the Results part, it is noted that « a combination of (cavity) SRS and surgical resection was 
offered to 5.7% ». It is a very low rate while it is the current standard of care. The authors should 
discussion this point and analyse this specific information in the most recent data set. 
 
 
 
Thank you for this valuable comment. As mentioned to Reviewer #1, SRS to the surgical cavity is not 
the “standard of care” in the UK. Our National Health Service supports cavity SRS if there is residual 
disease after the operation and only after MDT discussion with post-operative imaging. Therefore, 
the proportion of patients having cavity SRS will be lower than compared to the US. This has been 
outlined in the discussion. However, the authors believe that it is important to report differences in 
practice in different countries, to generate debate and potentially inform/change practice and 
therefore hope that this article will be a valuable contribution to an international journal like Neuro-
Oncology Practice. 
 
Lines 328-331 
“Furthermore, while SRS to the resection cavity is supported by NICE if there is residual disease, 
and after post-operative imaging, this may not be recommended at the initial NMDT. Therefore, a 
large proportion of patients will have had cavity SRS without this being captured in this study.” 
 
- The discussion regarding delaying submission to neuro-oncology multidisciplinary team is of 
particular interest. Is there a recommended maximal time interval to submit a case? 
 
Thank you for this interesting question. We are not aware of a maximal time interval recommended 
in the UK. All patients with a suspected new diagnosis of malignancy should be referred via a “2 week 
wait” pathway as per national guidelines. However, there is no timeframe for patients with existing 
diagnosis of cancer and these are usually referred to the neuro-oncology multidisciplinary team after 
diagnosis of brain metastasis. 
  
 
 
Reviewer #3: 
 
This study described the real world of the treatment on the cerebral metastases. At the same time, 
they also analyzed the factors influencing the decision-making from the neuro-oncology multi-
disciplinary team. Although a large number of information was missing, the data presented in this 
study is very interesting, and could be used as a baseline against which future multicenter, 
randomized controlled trials in CMs can be designed and adequately powered. 
 
One concern point. 
 
In the present study, surgical resection alone was given for 196 patents. A combination of (cavity) 
SRS and surgical resection was offered to 5.7% (n=60). A combination of surgery or SRS with 
radiotherapy was offered to 1.7% (n=18) and 0.5% (n=5), respectively. Therefore, a total of 279 
patients underwent surgical resection, which indicated that surgery was suggested more and more 
popular in NMDT. Could you analysis which factors are associated with the recommendation of 
surgical resection, KPS, the number of lesions, etc. ? 
 
Thank you for this interesting question. We looked at all the factors influencing multi-disciplinary 
team decision-making (as described in Table 5) and found that patients with age <65 years, 
Karnofsky-Performance Status ≥70, controlled primary disease status and brain metastases only 
were more likely to have surgery or SRS recommended (p<0.001). Also the location and histology of 
the primary tumor influenced the decision-making but to a lesser extent (p<0.05). Other factors like 
brain metastasis size, previous brain surgery, pre-operative neurological deficit did not influence the 
decision to recommend surgery for these patients (p>0.05). Furthermore, surgery compared to SRS 
was much more likely when patients had a single metastasis whereas patients with multiple 
metastases had SRS recommended more often (please see Table 4 for more details). 
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Abstract 
Background: Over the recent years an increasing number of patients with cerebral metastasis 
(CM) are being referred to the neuro-oncology multi-disciplinary team (NMDT). Our aim was 
to obtain a national picture of CM referrals, to assess and to assess referral volume and , quality 
of information provided and factors affecting NMDT decision-making. 
Methods: Prospective multicenter cohort study including all adult patients referred to NMDT 
with ≥1CM. Data was collected in neurosurgical units from 11/2017 to 02/2018. 
Demographics, primary disease, Karnofsky Performance Status (KPS), imaging and treatment 
recommendation were entered into an online database. 
Results: 1048 patients were analyzed from 24 neurosurgical units. Median age was 65[range 
21-93] years with a median number of 3[range 1-17] referrals per NMDT. The most common 
primary malignancies were lung (36.5%, n=383), breast (18.4%, n=193) and melanoma 
(12.0%, n=126). 51.6% (n=541) of the referrals were for solitary metastasis, and resulted in 
specialist intervention being offered in 67.5% (n=365). 38.2% (n=186) of patients being 
referred with multiple CMs were offered specialist treatment. NMDT decision-making was 
associated with number of CMs, age, KPS, primary disease status and extent of extracranial 
disease (univariate logistic regression, p<0.0001) as well as sentinel location and tumor 
histology (p<0.05). A delay in reaching an NMDT decision was identified in 18.6% (n=195). 
Conclusions: This study demonstrates a changing landscape of metastasis management in the 
UK and Ireland, including a trend away from adjuvant whole brain radiotherapy and 
specialist intervention being offered to a significant proportion of patients with multiple CMs. 
Poor quality or incomplete referrals cause delay in NMDT decision-making. 
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Keywords: brain tumor; British Neurosurgery Trainee Research Collaborative (BNTRC); 
cerebral metastasis; Management Evaluation of Metastasis in the BRAIN (MEMBRAIN); 
neuro-oncology multi-disciplinary team (NMDT) 
 
Importance of the Study: 
The study aim was to draw up a national picture of cerebral metastasis (CM) referrals and to 
assess whether decision-making matches the changing landscape of CM management both 
worldwide, and in light of the most recent National Institute of Health and Care Excellence 
(NICE) guidelines. This is the largest UK and Ireland study focusing on the management of 
CMs, stemming from the collaborative effort of 24 neuro-oncology multi-disciplinary teams 
(NMDT) throughout the country. This project allowed to prospectively collect a large database 
of CM patients (more than 1000 cases recorded). The results capture a changing culture in the 
treatment of CMs, with a shift away from adjuvant radiotherapy (offered to less than 3% of 
patients after either surgery or SRS) and with a significant proportion (38.6%) of patients with 
multiple CMs being offered specialist intervention (either surgery or SRS). Finally, the data 
presented in this study can be used as a baseline against which future multicenter, randomized 
controlled trials in CMs can be designed and adequately powered. 
 
Key points: 
 Confirmation of a national change in culture of referral and treatment pattern 
 38.2% of patients with multiple metastases are offered either surgery or SRS 
 Less than 3% of patients are offered adjuvant whole brain radiotherapy 
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Introduction 1 
The National Institute of Health and Care Excellence (NICE)1 Improving Outcomes Guidance 2 
(IOG) for brain and central nervous system (CNS) tumours of 2006 recommended that 3 
management of all patients with brain tumours should be guided by a neuro-oncology multi-4 
disciplinary team (NMDT) to ensure consensus opinion on patient care is reached.2 Since 5 
cerebral metastasis (CM) referrals to the weekly NMDT originate from a variety of sources, 6 
including the local Emergency Department (ED), District General Hospital (DGH), 7 
Oncologists or General Practitioners (GPs) and NMDT members have not seen these patients 8 
a priori, the provided referral information can be incomplete,3 potentially instigating a 9 
treatment delay while further clinical information is gathered and NMDT decision awaited. 10 
The initial design and set-up of the NMDT was aimed at patients requiring specialist 11 
intervention, and therefore commonly limited to a small group of patients presenting with a 12 
single metastasis and good prognosis from their systemic cancer.2 Over the recent years there 13 
has been a rise in the incidence of CMs encountered in clinical practice due to improved 14 
diagnostic imaging techniques, a global increase in the incidence of primary cancer and 15 
improved systemic treatments and overall survival.4-6 As a result, there are increasing numbers 16 
of patients being referred to the NMDT with CM, some of whom may be suitable for treatment 17 
and others who will not benefit and thus are not appropriate for any intervention due to 18 
advanced disseminated disease. 19 
The rationale for active intervention in CM was based upon studies from the late 1990s showing 20 
a survival advantage and/or decrease from neurologic death conferred by a combined approach 21 
of neurosurgery or stereotactic radiosurgery (SRS) with adjuvant whole-brain radiotherapy 22 
(WBRT) in patients with oligometastatic disease.7-10 A widely adopted prognostic scoring 23 
system used age, performance status, systemic disease burden and presence of extracranial 24 
metastases to stratify patients into three recursive partitioning analysis (RPA) classes with 25 
NOP-D-19-00065R1 
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significantly different survival which was subsequently validated in various populations.7 More 26 
recent prognostic scoring systems have included the type of primary cancer and identified that 27 
the survival of patients with CMs varies significantly by diagnosis.11 For each type of primary 28 
tumor, a disease-specific graded prognostic assessment (ds-GPA) score was derived to estimate 29 
survival.11-14 30 
However, there have been several recent changes in practice amongst specialists entailing a 31 
much more individualized approach in treatment decisions: Firstly, there is a move away from 32 
using WBRT, and SRS is now being favored for multiple metastases as well as being used as 33 
treatment to the surgical cavity after resection.15,16 Secondly, immunotherapy and targeted 34 
chemotherapy, such as checkpoint inhibitors, proto-oncogene BRAF V600E antibodies, or 35 
Anaplastic Lymphoma Kinase (ALK) inhibitors, have revolutionized the management of CMs 36 
from certain cancers such as melanoma and lung cancer.17,18 37 
While NICE guidelines in 2006 recommended referral to the NMDT only for cases in which 38 
either patients presented with solitary metastasis in good performance status with a prognosis 39 
warranting neurosurgical intervention or in cases where a referral was mandated in order to 40 
establish a diagnosis,2 the newly published NICE guidelines from 2018 recommend referral for 41 
all CMs.19 Equally, treatment recommendations have been updated: whilst formerly complete 42 
surgical removal of the solitary metastasis followed by postoperative WBRT was considered 43 
the mainstay of treatment, the new guidelines suggest a more complex approach, 44 
recommending: 1.) Surgery or SRS for solitary metastases with adjuvant SRS to surgical cavity 45 
in patients with one to three metastases, without adjuvant WBRT; 2.)  SRS/radiotherapy for 46 
patients with multiple metastases; 3.) WBRT only for patients who have not received surgery 47 
or SRS and who do not have non-small cell lung cancer.19 48 
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The aim of this study was to draw up a national picture of CM referrals and to assess whether 49 
decision-making matches the changing landscape of metastasis management both worldwide, 50 
and in light of the newly reformed NICE guidelines.20 51 
Furthermore, observational studies of CMs have been primarily of a retrospective nature and 52 
prospective studies have been restricted to a single centre.3,5,7,11 These limitations lead to 53 
inherent biases in practice and patient selection and may not reflect the current national practice 54 
in order to generate health economic models and allow future resource planning.21 Using 55 
prospectively collected data from multiple neuro-surgical units (NSUs), we aimed to assess the 56 
volume of CM referrals to the NMDT, the quality of referral information provided and its 57 
impact on NMDT decision-making. Thereby, the data presented in this study can be used as a 58 
baseline against which any future multicenter randomizsed controlled trials (RCTs) can be 59 
designed and adequately powered. 60 
 61 
Materials and Methods 62 
Study design 63 
A prospective multicenter observational study of CM management was conducted across 24 64 
NSUs in the United Kingdom and Ireland. Primary data collection took place over 4 months 65 
between November 2017 and February 2018 after an initial trial period at one centrer from 66 
September 2017 to October 2017 (see supplementary Figures 1-3 for information on monthly 67 
recruitment and centrer participation, respectively). All adult patients (≥18 years of age) 68 
referred to the NMDT with CM were included in the study. The NMDT was composed of a 69 
variety of team members including but not limited to: Consultant Neurosurgeon, Neurologist, 70 
Neuro-Radiologist, Neuro-Oncologist, Neuropathologist; Neuro-Oncology Clinical Nurse 71 
Specialists; Occupational and Speech and Language Therapists, Physiotherapists, coordinators 72 
and a Neuro-Psychologist, where available. The study protocol was designed by the British 73 
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Neurosurgical Trainee Research Collaborative (BNTRC)22 and approved by the Society of 74 
British Neurological Surgeons (SBNS) Academic Committee. The manuscript was written 75 
following the Strengthening the Reporting of Observational Studies in Epidemiology 76 
(STROBE) checklist.23 77 
 78 
Data collection and outcome measures 79 
Anonymized data were entered into Castor Electronic Data Capture (EDC), which is a secure 80 
online database, complying with the Department of Health Information Governance policy and 81 
meeting the data security standards of the Information Governance Toolkit of the Health and 82 
Social Care Information Centre. The audit and clinical governance committee of each 83 
participating hospital approved the study protocol. 84 
The following demographic and operative parameters were captured in the electronic Case 85 
Report Form (eCRF): age, gender, date of NMDT, presenting symptoms, Karnofsky (KPS) and 86 
Eastern Cooperative Oncology Group (ECOG)24 performance status, status/location/diagnosis 87 
of primary disease, treatment of primary disease, presence of extracranial metastasis, 88 
positive/negative molecular markers of primary tumor, status of extracranial disease (local vs 89 
metastatic, controlled vs uncontrolled), cranial imaging undertaken, number/size/location of 90 
cranial metastases, delay of NMDT decision, treatment recommendation (“specialist” 91 
interventions as recommended by a dedicated Neuro-Oncology center (Neuro-Oncologist, 92 
Neurosurgeon) located in a large tertiary referral unit: surgical resection, cerebrospinal fluid 93 
(CSF) diversion, SRS, cavity SRS; “non-specialist” treatment as provided by a  (General 94 
Oncologist): chemotherapy, immunotherapy, WBRT, local fractionated radiotherapy, best 95 
supportive care, other) and previous treatment of CM. RPA7 and ds-GPA11 was calculated for 96 
all referred cases, providing the required information was completed. 97 
 98 
NOP-D-19-00065R1 
 
10 
 
Formatted: Centered
Statistical analysis 99 
Descriptive statistics were used to characterize the patient population. Statistical analysis was 100 
performed using GraphPad Prism V7 and Stata/IC v.15.1 statistical package. Chi-squared test 101 
was used to assess the statistical significance of observed differences between cohorts 102 
undergoing specialist or non-specialist treatment. Univariate logistic regression was used to 103 
explore the relationship between primary outcome (Specialist vs. Non-specialist treatment) and 104 
a set of predictors. Differences in the primary outcome (Specialist vs. Non-specialist treatment) 105 
between RPA classes I-III were represented with bar plots and analyzed with a Chi-squared 106 
test for trend. 107 
 108 
Results 109 
Patient demographics, performance status, presenting symptoms 110 
In total 1048 patients were analyzed (Table1) and 55.5% (n=582) were female. Median age at 111 
referral was 65 years [range 21-93 years] and the median number of referrals per weekly 112 
NMDT was 3 [range 1-17]. The most common presenting symptoms were motor deficit 113 
(30.1%, n=315), headache (24.1%, n=253) and confusion (17.9%, n=188). 6.8% of patients 114 
(n=71) in our cohort presented with symptoms of raised intracranial pressure (ICP) and in 3.0% 115 
of cases (n=31) CMs were found incidentally. KPS was ≥70 in 54.8% (n=564), <70 in 18.3% 116 
(n=193) and not provided in 24.3% (n=255). 117 
 118 
Pre-treatment characteristics: Primary Cancer 119 
681 patients (65.0%) had a known primary diagnosis of cancer. The most common primary 120 
tumor locations were lung (36.5%, n=383), breast (18.4%, n=193) and melanoma (12.0%, 121 
n=126) (Table 2). In 5.2% (n=54) there was no extracranial disease. The primary tumor was 122 
controlled in 33.5% (n=351), not controlled in 22.0% (n=231) and this information was not 123 
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provided in 39.3% (n=412). 44.6% (n=467) of patients had extracranial metastases. The time 124 
interval between diagnosis of primary tumor and CM was ≤2 years in 33.7% (n=353) and 125 
unknown/not recorded in 43.5% (n=456). The status of markers of sensitivity to targeted 126 
chemotherapy in the primary cancer was unknown/not recorded in 71.3% of patients (n=747). 127 
 128 
 129 
 130 
Pre-treatment characteristics: Cerebral Metastasis 131 
51.6% (n=541) of patients were referred with a solitary CM. 31.0% (n=325) had two to four 132 
metastases (two metastases: 18.2% (n=191); three metastases: 8.9% (n=93); four metastases: 133 
3.9% (n=41)) and 15.4% (n=162) had five or more metastases (Table 3). Out of all patients 134 
referred, 14.7% (n=154) had undergone previous surgery for removal of CM and were referred 135 
back to the NMDT for discussion of recurrent disease. 136 
The most common sentinel locations of CM were the frontal lobe (38.7%, n=406), the 137 
cerebellum (19.4%, n=203) and the parietal lobe (14.6%, n=153). 83.3% (n=873) of patients 138 
underwent Magnetic Resonance Imaging (MRI) and 60.6% (n=635) of patients had a Computer 139 
Tomography (CT) scan of the head prior to NMDT referral. Gadolinium contrast was 140 
administered in n=836 (95.8% of MRI scans). In cases where MRI was not undertaken the 141 
most common reason given was that the scan was indicated but not performed before the 142 
NMDT (52.0%, n=91), followed by the second most common reason being that the referring 143 
team did not have a clinical indication to perform a MRI scan (27.4%, n=48). 144 
 145 
Treatment recommendation 146 
Specialist intervention (either SRS or surgical resection) was recommended in 52.6% (n=551) 147 
of patients (Table 4). Specialist intervention was recommended in 67.5% (n=365) of patients 148 
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with a solitary metastasis, and in 38.2% (n=186) of patients with multiple CMs. In particular, 149 
48.6% (n=158) of patients with two to four metastases and 17.3% (n=28) of patients with five 150 
or more metastases were offered specialist intervention. The most commonly offered 151 
intervention was SRS alone (20.8%, n=218), followed by surgical resection alone (18.7%, 152 
n=196). A combination of (cavity) SRS and surgical resection was offered to 5.7% (n=60). A 153 
combination of surgery or SRS with radiotherapy (WBRT or local fractionated radiotherapy) 154 
was offered to 1.7% (n=18) and 0.5% (n=5), respectively. Other surgical treatments offered to 155 
patients included a biopsy in 1.0% (n=11), out of which two were for cancer of unknown 156 
primary (CUP) and five for newly diagnosed patients, and a form of CSF diversion in 0.9% 157 
(n=9). 158 
In 42.7% (n=447) of patients, NMDT decision was to recommend non-specialist treatment 159 
either in the form of active oncology treatment (chemotherapy 1.7% (n=18), immunotherapy 160 
0.8% (n=8) or local fractionated radiotherapy 1.5% (n=16)) or palliative treatment (WBRT 161 
11.0% (n=115), best supportive care 17.2% (n=180)). 162 
In 18.6% (n=195) of patients there was a delay in the NMDT treatment recommendation given 163 
(median time to decision-making after initial discussion in MDT was 11 ± 112 days) due to 164 
lack of imaging (52.3%, n=102), missing referral information (27.2%, n=53) or waiting for 165 
further investigations/results (13.8%, n=27). 166 
 167 
Factors influencing NMDT decision-making 168 
Using univariate logistic regression we explored the relationship between the primary outcome 169 
(Specialist vs Non-specialist treatment recommendation) and independent predictors. We 170 
identified number of CM, age, KPS, primary disease status and extracranial disease as factors 171 
associated with the NMDT decision-making (Table 5, p<0.0001). Location of sentinel 172 
metastasis and histology of the primary tumor also showed a statistically significant association 173 
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with NMDT decision-making (p=0.047 and p=0.009, respectively). Factors that were not found 174 
to be associated with decision-making were time interval to diagnosis, size of sentinel 175 
metastasis, prior brain surgery, pre-operative neurological deficit, headache and delay in 176 
NMDT decision (p>0.05). 177 
 178 
 179 
 180 
Recursive tree 181 
With regards to RPA classes,7 only a small proportion of patients within our cohort were 182 
allocated to Class I (n = 84, Figure 1a). The majority of patients were either class II (n = 281) 183 
or class III (n = 190). RPA class I patients were managed surgically in the majority of cases 184 
(80.0%, n=68), class II was managed either surgically (63.7%, n=179) or non-surgically 185 
(36.3%, n=102; out of which WBRT was recommended in n=43 and best supportive care in 186 
n=30) and class III was managed non-surgically in the majority of cases (66.8%, n=127; out of 187 
which WBRT was recommended in n=25 and best supportive care in n=83).There was a 188 
statistically significant difference in surgical vs. non-surgical treatment between those three 189 
classes (Chi2trend p <0.0001; Figure 1a and supplementary Figure 4b). 190 
 191 
Validation of ds-GPA 192 
We applied ds-GPA classification for lung, melanoma, breast, renal and gastrointestinal (GI) 193 
tract cancers (Figure 1bc). Overall, the proportion of recommendation for specialist treatment 194 
tended to be higher in patients with a high ds-GPA score and therefore longer expected median 195 
survival as compared to patients with a low ds-GPA score but these differences were not 196 
statistically significant with our data. It is noteworthy that due to incomplete referrals, lacking 197 
KPS, molecular profile and patient age there was a loss in numbers of patients, which was 198 
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particularly evident in the breast and melanoma cancer group but also in GI cancers where KPS 199 
was the only prognostic factor for median survival within this particular classification. 200 
 201 
 202 
 203 
 204 
Discussion 205 
Pattern of CM referrals 206 
There have been three large RCTs investigating the role of surgical resection in the treatment 207 
of solitary CM,9,10,25,26 comparing surgical resection followed by radiotherapy versus 208 
radiotherapy alone. Two out of three RCTs found a statistically significant longer median 209 
survival and better quality of life in the surgical resection group. Two other large RCTs looked 210 
at the effect of SRS in combination with WBRT15,27 in the management of single or multiple 211 
CMs and found that a combination of the two treatment modalities may show improved 212 
neurological function and intracranial tumor control, however does not show improved median 213 
survival. These findings were confirmed by a meta-analysis of 27 RCTs.28 214 
Current NMDT management is based on a combination of these studies with the evolving 215 
literature. While WBRT has been the mainstay of treatment for decades, it has recently fallen 216 
out of favor due to its association with neurocognitive decline.16 Newer studies propose the use 217 
of SRS for multiple metastases and cavity SRS after surgical metastasis removal.15,16  218 
Additionally, advances in immunotherapy and targeted chemotherapy treatments offer 219 
alternatives to patients with a favorable mutation profile in melanoma and lung cancer.17,18 220 
 221 
In our cohort, 51.6% of patients were referred for treatment of a solitary metastasis. Within the 222 
subgroup of patients with multiple metastases, patients with two metastases were most 223 
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commonly referred (18.2% of total) followed by patients with five or more CMs (15.5% of 224 
total). The change in practice reflects the fact that 38.2% (n=186) of the patients referred with 225 
multiple metastases were recommended specialist intervention, as compared to ~10% of 226 
patients in a single-center series of 1640 patients from 2013-2015.27  227 
While treatment recommendation was limited to single CM in the former NICE guidelines of 228 
2006, the newer NICE guidelines of 2018 give some recommendations regarding multiple 229 
metastases management, however lacking any recommendation about surgical resection. 230 
Therefore offering an intervention (surgery or SRS) in patients with multiple metastases 231 
remains entirely at the discretion of the NMDT and the treating surgeon or oncologist. In our 232 
cohort specialist treatment was recommended in 38.2% of patients with multiple metastases 233 
suggesting evolving management strategies,287 even before the publication of the 2018 NICE 234 
guidelines.  235 
 236 
There have been some recent studies confirming an increase in the use of SRS alone for many 237 
patients with multiple CMs as a strategy to gain local control while minimizing cognitive 238 
effects associated with WBRT.3029 While the benefit of surgical management of multiple CMs 239 
is currently lacking class I evidence, there are indications that surgery in these patients may be 240 
safe and beneficial to achieve intracranial tumor control, particularly to address large 241 
metastases, causing mass effect.310 Furthermore, a recent study suggests that re-do surgery may 242 
also be a viable option in patients with recurrent CMs.321 243 
 244 
Referrals requiring specialist intervention 245 
In our cohort, 52.6% of patients required specialist intervention in the form of SRS or surgery. 246 
It is clear that the proportion of patients undergoing specialist treatment is negatively correlated 247 
with the number of metastases present at the time of referral.  248 
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 249 
Sills et al.332 commented in 2005 on the evolution of treatment modalities in patients with CMs, 250 
due to improvements in surgical technique, using neuronavigation, pre-surgical mapping343 and 251 
intra-operative monitoring techniques, alongside diagnostic/therapeutic advances in the 252 
management of systemic cancers.310,354 This may lead to a change in the role and timing of 253 
surgical resection as more and more (neo-)adjuvant systemic therapies become available 254 
making more patients eligible candidates for surgical resection. However, our cohort study 255 
confirmed that previously established factors7,11 (such as age, KPS, number of CMs, presence 256 
of extracranial disease and systemic disease status) still play a key role in specialist treatment 257 
recommendation in the form of either surgery or SRS, while stressing the importance of 258 
accurate disease staging at referral.332,365-410 One factor that could not be analyzed due to lack 259 
of data is the influence of molecular marker status on NMDT decision-making which may be 260 
crucial in some cancer subtypes to make the best decisions. 261 
In fact, after categorizing our cohort into groups based on the recursive tree two main things 262 
can be observed: firstly, a significant proportion of patients (18.3%) are referred with a KPS<70 263 
and therefore per se, fall into the category of patients with poor median survival7 and are 264 
therefore poor surgical candidates (albeit ~30% of those had specialist treatment recommended 265 
suggesting that there is a necessity to discuss these patients in the NMDT). Secondly, there was 266 
a large proportion of patients (24.3%) in whom the KPS was not provided by the referring 267 
team. Increasing compliance with KPS reporting at referral would therefore help streamline 268 
decision-making at NMDT. 269 
We found no evidence of an association between the following prognostic factors7 and NMDT 270 
decision-making in our cohort: prior brain surgery, time interval between primary and 271 
secondary tumor diagnosis (before/after 2 years), neurological dysfunction and/or headache at 272 
presentation. The fact that having undergone prior brain surgery for removal of metastasis 273 
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excluding further specialist intervention within our data supports the idea of re-do surgery as 274 
an option that can have good outcomes in selected patients.343 275 
 276 
Delay in MDT decision-making  277 
In approximately one fifth of patients referred (18.6%), there was a delay in NMDT decision-278 
making. The most common reasons given were incomplete referral information provided, lack 279 
of imaging availability for review and/or awaiting further investigations/results from the 280 
referring team. This may lead to increase in NMDT workload, as those factors are considered 281 
essential for the decision-making process. Nonetheless, the fact that NMDT decision was 282 
delayed did not influence the outcome of the treatment recommendation given (Table 5, 283 
p=0.278). Whether the delay in offered treatment has a negative impact on patient survival will 284 
have to be assessed in future studies. 285 
Potential solutions would include to: re-iterate to referring teams the importance of all the 286 
information required; identifying and supporting those teams, which repeatedly send 287 
incomplete referrals. New streamlining pathways could also be established including an 288 
emphasis on a uniform national proforma in which data (including molecular profiles) is 289 
collected continuously, perhaps even capturing national outcome data. A further advantage of 290 
this would be that all required data would be readily available and could be shared between all 291 
specialties (GPs, ED, Oncologists, Neurosurgeons, etc.). 292 
 293 
Validation of RPA and ds-GPA 294 
The use of RPA and ds-GPA has been previously validated.421 More recently, molecular 295 
subtypes of tumours have also been taken into account, first in breast432 and then in lung 296 
cancer.443 Overall, our data showed that the better the RPA class7 (i.e. RPA class I) the more 297 
likely the patient was to have specialist treatment recommended. Whilst there tended to be a 298 
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greater chance of specialist treatment with a higher ds-GPA score11,454, we did not find a 299 
statistically significant association with our data. 300 
 301 
One of the reasons for the compliance rate falling short of 100% could be the recent 302 
developments in surgical techniques leading to a wider variety of patients being considered for 303 
such treatments. A recent study of 71 patients at a single institution showed that the actual 304 
survival outcome exceeded expected outcome significantly in a well selected cohort of 305 
patients.5 This remains to be confirmed in a larger patient population. Another reason could be 306 
that more surgery is offered to the elderly as an increasing number of otherwise fit patients are 307 
referred in an ageing population.4527 308 
 309 
There have been efforts to develop new stratification tools such as the Barnholtz-Sloan index46, 310 
Score Index for Radiosurgery (SIR) and Basic Score for Brain Metastases (BSBM) amongst 311 
others6,47,48 to guide NMDT decision-making for this heterogeneous cohort of patients. These 312 
have not been widely adopted into clinical practice for a number of reasons, presumably due 313 
to the fact that most of these scores are based on survival data alone without considering other 314 
important factors such as quality of life and tumor recurrence. Other reasons may be related to 315 
the constant evolution of molecular profiling and new therapeutic targets.18,49 Overall, 316 
population-based studies are not always as good in predicting individual outcome and it is 317 
evident that CM management has become very complex and a much more individualized 318 
approach is being applied. In the near future, one of these may be complemented by the use of 319 
imaging as a potential biomarker.50 320 
 321 
Data Generalizability and limitations of this study 322 
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The primary advantage of this study is the multicenter nature allowing for a large sample size. 323 
Three quarters of neurosurgical centers in the United Kingdom & Ireland participated in this 324 
cohort study, which gives a reflection on national management of CM referrals. Regional 325 
homogeneity of the referred patient population and NMDT treatment recommendation 326 
provided is of vital importance to plan future RCTs, inform health policy makers (including 327 
NICE), generate health economic models and assist in national resource allocation. In future, 328 
we would welcome a prospective national database for CM referrals that captures national 329 
outcome data. 330 
One of the limitations of this study has been that some of the referral information has been 331 
largely incomplete or missing as a whole. This limitation lies within the nature of this study 332 
and can be largely attributed to lack of information at the time of referral and does not reflect 333 
on the quality of data entry. 334 
Furthermore, while SRS to the resection cavity is supported by NICE if there is residual disease 335 
documented , and afterby post-operative imagingMRI, this may not be recommended at the 336 
initial NMDT. Therefore, a large proportion of patients will have had cavity SRS without this 337 
being captured in this study. 338 
 339 
Conclusions 340 
The development of new NICE guidelines will lead to an increase in NMDT workload. Our 341 
prospective study identified a delay in NMDT decision-making in approximately one in five 342 
patients. Specialist intervention was offered to 67.5% of patients with single CM and 38.2% of 343 
patients with multiple CMs, hence confirming a national change in culture of referral and 344 
treatment patterns, including a general trend away from adjuvant WBRT and specialist 345 
treatment being more frequently offered in multiple CMs.  346 
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Figure 1: Recursive Partitioning Analysis (RPA) of our study patients and treatment 
recommendation per disease specific-Graded Prognostic Assessment (ds-GPA)  
(A) The recursive tree (adapted from Gaspar et al) is a tool to classify patients into Class I-III. 
Patients with KPS<70 are categorized as Class III. Patients with KPS≥70, controlled primary 
disease, age<65 years and no extracranial metastases are classified as Class I. All other patients 
are classified as Class II. In our cohort the KPS was not available (NA) in ~25% of patients; 
(B) Treatment recommendation (specialist/surgery vs non-specialist/no surgery) per RPA class 
depicted in bar plots. Chi2trend showed p<0.0001. (C) Patients were grouped into ds-GPA as 
previously described by Sperduto et al. The bar plots demonstrate the treatment 
recommendation (specialist/surgery vs non-specialist/no surgery) per ds-GPA. There tended to 
be a higher proportion of recommended specialist treatment in patients with a higher ds-GPA 
score, however these differences were not statistically significant with our data. 
  
NOP-D-19-00065R1 
 
28 
 
Formatted: Centered
Supplementary material: 
Supplementary Figure 1: Participation of neurosurgical centers. 
The graph demonstrates the monthly participation of neurosurgical centers across the country 
with the non-cumulative number of centers depicted at the bottom. Overall 24/32 neurosurgical 
units participated during this study. 
Supplementary Figure 2: Recruitment of patients. 
A total number of 1048 patients were included in this study. The non-cumulative number of 
patients entered onto Castor EDC per month is depicted at the bottom. 
Supplementary Figure 3: Recruitment per region in the country. 
London and England contributed the most patients during this study. A total number of 6 
centers in Scotland, Wales and Ireland participated in this study. Northern Ireland did not 
take part. 
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Abstract 
Background: Over the recent years an increasing number of patients with cerebral metastasis 
(CM) are being referred to the neuro-oncology multi-disciplinary team (NMDT). Our aim was 
to obtain a national picture of CM referrals, to assess referral volume and quality and factors 
affecting NMDT decision-making. 
Methods: Prospective multicenter cohort study including all adult patients referred to NMDT 
with ≥1CM. Data was collected in neurosurgical units from 11/2017 to 02/2018. 
Demographics, primary disease, Karnofsky Performance Status (KPS), imaging and treatment 
recommendation were entered into an online database. 
Results: 1048 patients were analyzed from 24 neurosurgical units. Median age was 65[range 
21-93] years with a median number of 3[range 1-17] referrals per NMDT. The most common 
primary malignancies were lung (36.5%, n=383), breast (18.4%, n=193) and melanoma 
(12.0%, n=126). 51.6% (n=541) of the referrals were for solitary metastasis, and resulted in 
specialist intervention being offered in 67.5% (n=365). 38.2% (n=186) of patients being 
referred with multiple CMs were offered specialist treatment. NMDT decision-making was 
associated with number of CMs, age, KPS, primary disease status and extent of extracranial 
disease (univariate logistic regression, p<0.0001) as well as sentinel location and tumor 
histology (p<0.05). A delay in reaching an NMDT decision was identified in 18.6% (n=195). 
Conclusions: This study demonstrates a changing landscape of metastasis management in the 
UK and Ireland, including a trend away from adjuvant whole brain radiotherapy and 
specialist intervention being offered to a significant proportion of patients with multiple CMs. 
Poor quality or incomplete referrals cause delay in NMDT decision-making. 
 
Keywords: brain tumor; BNTRC; metastasis; multi-disciplinary team 
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Introduction 1 
The National Institute of Health and Care Excellence (NICE)1 Improving Outcomes Guidance 2 
(IOG) for brain and central nervous system (CNS) tumours of 2006 recommended that 3 
management of all patients with brain tumours should be guided by a neuro-oncology multi-4 
disciplinary team (NMDT) to ensure consensus opinion on patient care is reached.2 Since 5 
cerebral metastasis (CM) referrals to the weekly NMDT originate from a variety of sources, 6 
including the local Emergency Department (ED), District General Hospital (DGH), 7 
Oncologists or General Practitioners (GPs) and NMDT members have not seen these patients 8 
a priori, the provided referral information can be incomplete,3 potentially instigating a 9 
treatment delay while further clinical information is gathered and NMDT decision awaited. 10 
The initial design and set-up of the NMDT was aimed at patients requiring specialist 11 
intervention, and therefore commonly limited to a small group of patients presenting with a 12 
single metastasis and good prognosis from their systemic cancer.2 Over the recent years there 13 
has been a rise in the incidence of CMs encountered in clinical practice due to improved 14 
diagnostic imaging techniques, a global increase in the incidence of primary cancer and 15 
improved systemic treatments and overall survival.4-6 As a result, there are increasing numbers 16 
of patients being referred to the NMDT with CM, some of whom may be suitable for treatment 17 
and others who will not benefit and thus are not appropriate for any intervention due to 18 
advanced disseminated disease. 19 
The rationale for active intervention in CM was based upon studies from the late 1990s showing 20 
a survival advantage and/or decrease from neurologic death conferred by a combined approach 21 
of neurosurgery or stereotactic radiosurgery (SRS) with adjuvant whole-brain radiotherapy 22 
(WBRT) in patients with oligometastatic disease.7-10 A widely adopted prognostic scoring 23 
system used age, performance status, systemic disease burden and presence of extracranial 24 
metastases to stratify patients into three recursive partitioning analysis (RPA) classes with 25 
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significantly different survival which was subsequently validated in various populations.7 More 26 
recent prognostic scoring systems have included the type of primary cancer and identified that 27 
the survival of patients with CMs varies significantly by diagnosis.11 For each type of primary 28 
tumor, a disease-specific graded prognostic assessment (ds-GPA) score was derived to estimate 29 
survival.11-14 30 
However, there have been several recent changes in practice amongst specialists entailing a 31 
much more individualized approach in treatment decisions: Firstly, there is a move away from 32 
using WBRT, and SRS is now being favored for multiple metastases as well as being used as 33 
treatment to the surgical cavity after resection.15,16 Secondly, immunotherapy and targeted 34 
chemotherapy, such as checkpoint inhibitors, proto-oncogene BRAF V600E antibodies, or 35 
Anaplastic Lymphoma Kinase (ALK) inhibitors, have revolutionized the management of CMs 36 
from certain cancers such as melanoma and lung cancer.17,18 37 
While NICE guidelines in 2006 recommended referral to the NMDT only for cases in which 38 
either patients presented with solitary metastasis in good performance status with a prognosis 39 
warranting neurosurgical intervention or in cases where a referral was mandated in order to 40 
establish a diagnosis,2 the newly published NICE guidelines from 2018 recommend referral for 41 
all CMs.19 Equally, treatment recommendations have been updated: whilst formerly complete 42 
surgical removal of the solitary metastasis followed by postoperative WBRT was considered 43 
the mainstay of treatment, the new guidelines suggest a more complex approach, 44 
recommending: 1.) Surgery or SRS for solitary metastases with adjuvant SRS to surgical cavity 45 
in patients with one to three metastases, without adjuvant WBRT; 2.)  SRS/radiotherapy for 46 
patients with multiple metastases; 3.) WBRT only for patients who have not received surgery 47 
or SRS and who do not have non-small cell lung cancer.19 48 
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The aim of this study was to draw up a national picture of CM referrals and to assess whether 49 
decision-making matches the changing landscape of metastasis management both worldwide, 50 
and in light of the newly reformed NICE guidelines.20 51 
Furthermore, observational studies of CMs have been primarily of a retrospective nature and 52 
prospective studies have been restricted to a single centre.3,5,7,11 These limitations lead to 53 
inherent biases in practice and patient selection and may not reflect the current national practice 54 
in order to generate health economic models and allow future resource planning.21 Using 55 
prospectively collected data from multiple neuro-surgical units (NSUs), we aimed to assess the 56 
volume of CM referrals to the NMDT, the quality of referral information provided and its 57 
impact on NMDT decision-making. Thereby, the data presented in this study can be used as a 58 
baseline against which any future multicenter randomized controlled trials (RCTs) can be 59 
designed and adequately powered. 60 
 61 
Materials and Methods 62 
Study design 63 
A prospective multicenter observational study of CM management was conducted across 24 64 
NSUs in the United Kingdom and Ireland. Primary data collection took place over 4 months 65 
between November 2017 and February 2018 after an initial trial period at one center from 66 
September 2017 to October 2017 (see supplementary Figures 1-3 for information on monthly 67 
recruitment and center participation, respectively). All adult patients (≥18 years of age) referred 68 
to the NMDT with CM were included in the study. The NMDT was composed of a variety of 69 
team members including but not limited to: Consultant Neurosurgeon, Neurologist, Neuro-70 
Radiologist, Neuro-Oncologist, Neuropathologist; Neuro-Oncology Clinical Nurse Specialists; 71 
Occupational and Speech and Language Therapists, Physiotherapists, coordinators and a 72 
Neuro-Psychologist, where available. The study protocol was designed by the British 73 
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Neurosurgical Trainee Research Collaborative (BNTRC)22 and approved by the Society of 74 
British Neurological Surgeons (SBNS) Academic Committee. The manuscript was written 75 
following the Strengthening the Reporting of Observational Studies in Epidemiology 76 
(STROBE) checklist.23 77 
 78 
Data collection and outcome measures 79 
Anonymized data were entered into Castor Electronic Data Capture (EDC), which is a secure 80 
online database, complying with the Department of Health Information Governance policy and 81 
meeting the data security standards of the Information Governance Toolkit of the Health and 82 
Social Care Information Centre. The audit and clinical governance committee of each 83 
participating hospital approved the study protocol. 84 
The following demographic and operative parameters were captured in the electronic Case 85 
Report Form (eCRF): age, gender, date of NMDT, presenting symptoms, Karnofsky (KPS) and 86 
Eastern Cooperative Oncology Group (ECOG)24 performance status, status/location/diagnosis 87 
of primary disease, treatment of primary disease, presence of extracranial metastasis, 88 
positive/negative molecular markers of primary tumor, status of extracranial disease (local vs 89 
metastatic, controlled vs uncontrolled), cranial imaging undertaken, number/size/location of 90 
cranial metastases, delay of NMDT decision, treatment recommendation (“specialist” 91 
interventions as recommended by a dedicated Neuro-Oncology center (Neuro-Oncologist, 92 
Neurosurgeon) located in a large tertiary referral unit: surgical resection, cerebrospinal fluid 93 
(CSF) diversion, SRS, cavity SRS; “non-specialist” treatment as provided by a General 94 
Oncologist: chemotherapy, immunotherapy, WBRT, local fractionated radiotherapy, best 95 
supportive care, other) and previous treatment of CM. RPA7 and ds-GPA11 was calculated for 96 
all referred cases, providing the required information was completed. 97 
Statistical analysis 98 
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Descriptive statistics were used to characterize the patient population. Statistical analysis was 99 
performed using GraphPad Prism V7 and Stata/IC v.15.1 statistical package. Chi-squared test 100 
was used to assess the statistical significance of observed differences between cohorts 101 
undergoing specialist or non-specialist treatment. Univariate logistic regression was used to 102 
explore the relationship between primary outcome (Specialist vs. Non-specialist treatment) and 103 
a set of predictors. Differences in the primary outcome (Specialist vs. Non-specialist treatment) 104 
between RPA classes I-III were represented with bar plots and analyzed with a Chi-squared 105 
test for trend. 106 
 107 
Results 108 
Patient demographics, performance status, presenting symptoms 109 
In total 1048 patients were analyzed (Table1) and 55.5% (n=582) were female. Median age at 110 
referral was 65 years [range 21-93 years] and the median number of referrals per weekly 111 
NMDT was 3 [range 1-17]. The most common presenting symptoms were motor deficit 112 
(30.1%, n=315), headache (24.1%, n=253) and confusion (17.9%, n=188). 6.8% of patients 113 
(n=71) in our cohort presented with symptoms of raised intracranial pressure (ICP) and in 3.0% 114 
of cases (n=31) CMs were found incidentally. KPS was ≥70 in 54.8% (n=564), <70 in 18.3% 115 
(n=193) and not provided in 24.3% (n=255). 116 
 117 
Pre-treatment characteristics: Primary Cancer 118 
681 patients (65.0%) had a known primary diagnosis of cancer. The most common primary 119 
tumor locations were lung (36.5%, n=383), breast (18.4%, n=193) and melanoma (12.0%, 120 
n=126) (Table 2). In 5.2% (n=54) there was no extracranial disease. The primary tumor was 121 
controlled in 33.5% (n=351), not controlled in 22.0% (n=231) and this information was not 122 
provided in 39.3% (n=412). 44.6% (n=467) of patients had extracranial metastases. The time 123 
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interval between diagnosis of primary tumor and CM was ≤2 years in 33.7% (n=353) and 124 
unknown/not recorded in 43.5% (n=456). The status of markers of sensitivity to targeted 125 
chemotherapy in the primary cancer was unknown/not recorded in 71.3% of patients (n=747). 126 
 127 
Pre-treatment characteristics: Cerebral Metastasis 128 
51.6% (n=541) of patients were referred with a solitary CM. 31.0% (n=325) had two to four 129 
metastases (two metastases: 18.2% (n=191); three metastases: 8.9% (n=93); four metastases: 130 
3.9% (n=41)) and 15.4% (n=162) had five or more metastases (Table 3). Out of all patients 131 
referred, 14.7% (n=154) had undergone previous surgery for removal of CM and were referred 132 
back to the NMDT for discussion of recurrent disease. 133 
The most common sentinel locations of CM were the frontal lobe (38.7%, n=406), the 134 
cerebellum (19.4%, n=203) and the parietal lobe (14.6%, n=153). 83.3% (n=873) of patients 135 
underwent Magnetic Resonance Imaging (MRI) and 60.6% (n=635) of patients had a Computer 136 
Tomography (CT) scan of the head prior to NMDT referral. Gadolinium contrast was 137 
administered in n=836 (95.8% of MRI scans). In cases where MRI was not undertaken the 138 
most common reason given was that the scan was indicated but not performed before the 139 
NMDT (52.0%, n=91), followed by the second most common reason being that the referring 140 
team did not have a clinical indication to perform a MRI scan (27.4%, n=48). 141 
 142 
Treatment recommendation 143 
Specialist intervention (either SRS or surgical resection) was recommended in 52.6% (n=551) 144 
of patients (Table 4). Specialist intervention was recommended in 67.5% (n=365) of patients 145 
with a solitary metastasis, and in 38.2% (n=186) of patients with multiple CMs. In particular, 146 
48.6% (n=158) of patients with two to four metastases and 17.3% (n=28) of patients with five 147 
or more metastases were offered specialist intervention. The most commonly offered 148 
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intervention was SRS alone (20.8%, n=218), followed by surgical resection alone (18.7%, 149 
n=196). A combination of (cavity) SRS and surgical resection was offered to 5.7% (n=60). A 150 
combination of surgery or SRS with radiotherapy (WBRT or local fractionated radiotherapy) 151 
was offered to 1.7% (n=18) and 0.5% (n=5), respectively. Other surgical treatments offered to 152 
patients included a biopsy in 1.0% (n=11), out of which two were for cancer of unknown 153 
primary (CUP) and five for newly diagnosed patients, and a form of CSF diversion in 0.9% 154 
(n=9). 155 
In 42.7% (n=447) of patients, NMDT decision was to recommend non-specialist treatment 156 
either in the form of active oncology treatment (chemotherapy 1.7% (n=18), immunotherapy 157 
0.8% (n=8) or local fractionated radiotherapy 1.5% (n=16)) or palliative treatment (WBRT 158 
11.0% (n=115), best supportive care 17.2% (n=180)). 159 
In 18.6% (n=195) of patients there was a delay in the NMDT treatment recommendation given 160 
(median time to decision-making after initial discussion in MDT was 11 ± 112 days) due to 161 
lack of imaging (52.3%, n=102), missing referral information (27.2%, n=53) or waiting for 162 
further investigations/results (13.8%, n=27). 163 
 164 
Factors influencing NMDT decision-making 165 
Using univariate logistic regression we explored the relationship between the primary outcome 166 
(Specialist vs Non-specialist treatment recommendation) and independent predictors. We 167 
identified number of CM, age, KPS, primary disease status and extracranial disease as factors 168 
associated with the NMDT decision-making (Table 5, p<0.0001). Location of sentinel 169 
metastasis and histology of the primary tumor also showed a statistically significant association 170 
with NMDT decision-making (p=0.047 and p=0.009, respectively). Factors that were not found 171 
to be associated with decision-making were time interval to diagnosis, size of sentinel 172 
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metastasis, prior brain surgery, pre-operative neurological deficit, headache and delay in 173 
NMDT decision (p>0.05). 174 
 175 
Recursive tree 176 
With regards to RPA classes,7 only a small proportion of patients within our cohort were 177 
allocated to Class I (n = 84, Figure 1a). The majority of patients were either class II (n = 281) 178 
or class III (n = 190). RPA class I patients were managed surgically in the majority of cases 179 
(80.0%, n=68), class II was managed either surgically (63.7%, n=179) or non-surgically 180 
(36.3%, n=102; out of which WBRT was recommended in n=43 and best supportive care in 181 
n=30) and class III was managed non-surgically in the majority of cases (66.8%, n=127; out of 182 
which WBRT was recommended in n=25 and best supportive care in n=83).There was a 183 
statistically significant difference in surgical vs. non-surgical treatment between those three 184 
classes (Chi2trend p <0.0001; Figure 1a and supplementary Figure 4). 185 
 186 
Validation of ds-GPA 187 
We applied ds-GPA classification for lung, melanoma, breast, renal and gastrointestinal (GI) 188 
tract cancers (Figure 1b). Overall, the proportion of recommendation for specialist treatment 189 
tended to be higher in patients with a high ds-GPA score and therefore longer expected median 190 
survival as compared to patients with a low ds-GPA score but these differences were not 191 
statistically significant with our data. It is noteworthy that due to incomplete referrals, lacking 192 
KPS, molecular profile and patient age there was a loss in numbers of patients, which was 193 
particularly evident in the breast and melanoma cancer group but also in GI cancers where KPS 194 
was the only prognostic factor for median survival within this particular classification. 195 
 196 
Discussion 197 
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Pattern of CM referrals 198 
There have been three large RCTs investigating the role of surgical resection in the treatment 199 
of solitary CM,9,10,25,26 comparing surgical resection followed by radiotherapy versus 200 
radiotherapy alone. Two out of three RCTs found a statistically significant longer median 201 
survival and better quality of life in the surgical resection group. Two other large RCTs looked 202 
at the effect of SRS in combination with WBRT15,27 in the management of single or multiple 203 
CMs and found that a combination of the two treatment modalities may show improved 204 
neurological function and intracranial tumor control, however does not show improved median 205 
survival. These findings were confirmed by a meta-analysis of 27 RCTs.28 206 
Current NMDT management is based on a combination of these studies with the evolving 207 
literature. While WBRT has been the mainstay of treatment for decades, it has recently fallen 208 
out of favor due to its association with neurocognitive decline.16 Newer studies propose the use 209 
of SRS for multiple metastases and cavity SRS after surgical metastasis removal.15,16  210 
Additionally, advances in immunotherapy and targeted chemotherapy treatments offer 211 
alternatives to patients with a favorable mutation profile in melanoma and lung cancer.17,18 212 
 213 
In our cohort, 51.6% of patients were referred for treatment of a solitary metastasis. Within the 214 
subgroup of patients with multiple metastases, patients with two metastases were most 215 
commonly referred (18.2% of total) followed by patients with five or more CMs (15.5% of 216 
total). The change in practice reflects the fact that 38.2% (n=186) of the patients referred with 217 
multiple metastases were recommended specialist intervention, as compared to ~10% of 218 
patients in a single-center series of 1640 patients from 2013-2015.27  219 
While treatment recommendation was limited to single CM in the former NICE guidelines of 220 
2006, the newer NICE guidelines of 2018 give some recommendations regarding multiple 221 
metastases management, however lacking any recommendation about surgical resection. 222 
NOP-D-19-00065R1 
 
13 
 
Therefore offering an intervention (surgery or SRS) in patients with multiple metastases 223 
remains entirely at the discretion of the NMDT and the treating surgeon or oncologist. In our 224 
cohort specialist treatment was recommended in 38.2% of patients with multiple metastases 225 
suggesting evolving management strategies,28 even before the publication of the 2018 NICE 226 
guidelines.  227 
 228 
There have been some recent studies confirming an increase in the use of SRS alone for many 229 
patients with multiple CMs as a strategy to gain local control while minimizing cognitive 230 
effects associated with WBRT.30 While the benefit of surgical management of multiple CMs 231 
is currently lacking class I evidence, there are indications that surgery in these patients may be 232 
safe and beneficial to achieve intracranial tumor control, particularly to address large 233 
metastases, causing mass effect.31 Furthermore, a recent study suggests that re-do surgery may 234 
also be a viable option in patients with recurrent CMs.32 235 
 236 
Referrals requiring specialist intervention 237 
In our cohort, 52.6% of patients required specialist intervention in the form of SRS or surgery. 238 
It is clear that the proportion of patients undergoing specialist treatment is negatively correlated 239 
with the number of metastases present at the time of referral.  240 
 241 
Sills et al.33 commented in 2005 on the evolution of treatment modalities in patients with CMs, 242 
due to improvements in surgical technique, using neuronavigation, pre-surgical mapping34 and 243 
intra-operative monitoring techniques, alongside diagnostic/therapeutic advances in the 244 
management of systemic cancers.31,35 This may lead to a change in the role and timing of 245 
surgical resection as more and more (neo-)adjuvant systemic therapies become available 246 
making more patients eligible candidates for surgical resection. However, our cohort study 247 
NOP-D-19-00065R1 
 
14 
 
confirmed that previously established factors7,11 (such as age, KPS, number of CMs, presence 248 
of extracranial disease and systemic disease status) still play a key role in specialist treatment 249 
recommendation in the form of either surgery or SRS, while stressing the importance of 250 
accurate disease staging at referral.33,36-41 One factor that could not be analyzed due to lack of 251 
data is the influence of molecular marker status on NMDT decision-making which may be 252 
crucial in some cancer subtypes to make the best decisions. 253 
In fact, after categorizing our cohort into groups based on the recursive tree two main things 254 
can be observed: firstly, a significant proportion of patients (18.3%) are referred with a KPS<70 255 
and therefore per se, fall into the category of patients with poor median survival7 and are 256 
therefore poor surgical candidates (albeit ~30% of those had specialist treatment recommended 257 
suggesting that there is a necessity to discuss these patients in the NMDT). Secondly, there was 258 
a large proportion of patients (24.3%) in whom the KPS was not provided by the referring 259 
team. Increasing compliance with KPS reporting at referral would therefore help streamline 260 
decision-making at NMDT. 261 
We found no evidence of an association between the following prognostic factors7 and NMDT 262 
decision-making in our cohort: prior brain surgery, time interval between primary and 263 
secondary tumor diagnosis (before/after 2 years), neurological dysfunction and/or headache at 264 
presentation. The fact that having undergone prior brain surgery for removal of metastasis 265 
excluding further specialist intervention within our data supports the idea of re-do surgery as 266 
an option that can have good outcomes in selected patients.34 267 
 268 
Delay in MDT decision-making  269 
In approximately one fifth of patients referred (18.6%), there was a delay in NMDT decision-270 
making. The most common reasons given were incomplete referral information provided, lack 271 
of imaging availability for review and/or awaiting further investigations/results from the 272 
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referring team. This may lead to increase in NMDT workload, as those factors are considered 273 
essential for the decision-making process. Nonetheless, the fact that NMDT decision was 274 
delayed did not influence the outcome of the treatment recommendation given (Table 5, 275 
p=0.278). Whether the delay in offered treatment has a negative impact on patient survival will 276 
have to be assessed in future studies. 277 
Potential solutions would include to: re-iterate to referring teams the importance of all the 278 
information required; identifying and supporting those teams, which repeatedly send 279 
incomplete referrals. New streamlining pathways could also be established including an 280 
emphasis on a uniform national proforma in which data (including molecular profiles) is 281 
collected continuously, perhaps even capturing national outcome data. A further advantage of 282 
this would be that all required data would be readily available and could be shared between all 283 
specialties (GPs, ED, Oncologists, Neurosurgeons, etc.). 284 
 285 
Validation of RPA and ds-GPA 286 
The use of RPA and ds-GPA has been previously validated.42 More recently, molecular 287 
subtypes of tumours have also been taken into account, first in breast43 and then in lung 288 
cancer.44 Overall, our data showed that the better the RPA class7 (i.e. RPA class I) the more 289 
likely the patient was to have specialist treatment recommended. Whilst there tended to be a 290 
greater chance of specialist treatment with a higher ds-GPA score11,45, we did not find a 291 
statistically significant association with our data. 292 
 293 
One of the reasons for the compliance rate falling short of 100% could be the recent 294 
developments in surgical techniques leading to a wider variety of patients being considered for 295 
such treatments. A recent study of 71 patients at a single institution showed that the actual 296 
survival outcome exceeded expected outcome significantly in a well selected cohort of 297 
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patients.5 This remains to be confirmed in a larger patient population. Another reason could be 298 
that more surgery is offered to the elderly as an increasing number of otherwise fit patients are 299 
referred in an ageing population.27 300 
 301 
There have been efforts to develop new stratification tools such as the Barnholtz-Sloan index46, 302 
Score Index for Radiosurgery (SIR) and Basic Score for Brain Metastases (BSBM) amongst 303 
others6,47,48 to guide NMDT decision-making for this heterogeneous cohort of patients. These 304 
have not been widely adopted into clinical practice for a number of reasons, presumably due 305 
to the fact that most of these scores are based on survival data alone without considering other 306 
important factors such as quality of life and tumor recurrence. Other reasons may be related to 307 
the constant evolution of molecular profiling and new therapeutic targets.18,49 Overall, 308 
population-based studies are not always as good in predicting individual outcome and it is 309 
evident that CM management has become very complex and a much more individualized 310 
approach is being applied. In the near future, one of these may be complemented by the use of 311 
imaging as a potential biomarker.50 312 
 313 
Data Generalizability and limitations of this study 314 
The primary advantage of this study is the multicenter nature allowing for a large sample size. 315 
Three quarters of neurosurgical centers in the United Kingdom & Ireland participated in this 316 
cohort study, which gives a reflection on national management of CM referrals. Regional 317 
homogeneity of the referred patient population and NMDT treatment recommendation 318 
provided is of vital importance to plan future RCTs, inform health policy makers (including 319 
NICE), generate health economic models and assist in national resource allocation. In future, 320 
we would welcome a prospective national database for CM referrals that captures national 321 
outcome data. 322 
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One of the limitations of this study has been that some of the referral information has been 323 
largely incomplete or missing as a whole. This limitation lies within the nature of this study 324 
and can be largely attributed to lack of information at the time of referral and does not reflect 325 
on the quality of data entry. 326 
Furthermore, while SRS to the resection cavity is supported by NICE if there is residual disease 327 
documented by post-operative MRI, this may not be recommended at the initial NMDT. 328 
Therefore, a proportion of patients will have had cavity SRS without this being captured in this 329 
study. 330 
 331 
Conclusions 332 
The development of new NICE guidelines will lead to an increase in NMDT workload. Our 333 
prospective study identified a delay in NMDT decision-making in approximately one in five 334 
patients. Specialist intervention was offered to 67.5% of patients with single CM and 38.2% of 335 
patients with multiple CMs, hence confirming a national change in culture of referral and 336 
treatment patterns, including a general trend away from adjuvant WBRT and specialist 337 
treatment being more frequently offered in multiple CMs.  338 
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Table 1: Patient demographics, performance status, presenting symptoms 
Variable 
Total 
N 
1048 
% 
100.0 
Gender 
- Female 
- Male 
 
582 
466 
 
55.5 
44.5 
Age 
- <40 
- 40-44 
- 45-49 
- 50-54 
- 55-59 
- 60-64 
- 65-69 
- ≥70 
- NAa 
 
43 
38 
57 
84 
120 
143 
176 
379 
8 
 
4.1 
3.6 
5.4 
8.0 
11.5 
13.6 
16.8 
36.2 
0.8 
KPSb 
- 90-100 
- 70-80 
- 50-60 
- 30-40 
- 10-20 
- NAa 
 
336 
238 
145 
35 
13 
255 
 
32.1 
22.7 
13.8 
3.3 
1.2 
24.3 
WHOc Performance Status 
- 0 
- 1 
- 2 
- 3 
- 4 
- NAa 
 
187 
369 
184 
81 
22 
205 
 
17.8 
35.2 
17.6 
7.7 
2.1 
19.6 
Presenting Symptoms 
- Headache 
- Motor deficit 
- Speech deficit 
- Visual deficit 
- Seizure 
- Confusion 
- Screening 
- Ataxia/LOCd/Falls 
- Nausea/vomiting/raised ICPe 
- Weight loss/fatigue/lethargy 
- Incidental finding 
- Other/unknown 
 
253 
315 
128 
67 
115 
188 
141 
133 
71 
26 
31 
61 
 
24.1 
30.1 
12.2 
6.4 
11.0 
17.9 
13.5 
12.7 
6.8 
2.5 
3.0 
5.8 
 
a Not available = unknown or not recorded 
b Karnofsky-Performance Status 
c World Health Organization Performance Status 
d Loss of consciousness 
e Intracranial Pressure 
Table 1 Click here to access/download;Table;Brain mets_Table
1_10042019.docx
Table 2: Pre-treatment characteristics: Primary Cancer 
Variable 
Total 
N 
1048 
% 
100.0 
New diagnosis of cancer 
- yes 
- no 
- CUPa 
- NAb 
 
302 
681 
58 
7 
 
28.8 
65.0 
5.5 
0.7 
Location of Primary 
- Lung 
- Breast 
- Melanoma 
- Upper GIc Tract 
- Lower GIc Tract 
- Kidney 
- Prostate 
- Genito-urinary 
- Multiple 
- Other 
- CUPa/NAb 
 
383 
193 
126 
34 
58 
49 
13 
46 
23 
43 
80 
 
36.5 
18.4 
12.0 
3.2 
5.5 
4.7 
1.2 
4.4 
2.2 
4.1 
7.6 
Extracranial disease 
- none 
- controlled 
 
- uncontrolled 
 
- NAb 
 
 
 Primary site disease only 
 Metastatic disease 
 Primary site disease only 
 Metastatic disease 
 
54 
194 
157 
63 
168 
412 
 
5.2 
18.5 
15.0 
6.0 
16.0 
39.3 
Molecular Markers 
- positive 
- negative 
- NAb 
 
216 
108 
747 
 
20.6 
10.3 
71.3 
Time intervald 
- ≤ 2 years 
- > 2years 
- NAb 
 
353 
239 
456 
 
33.7 
22.8 
43.5 
Extracranial metastasis 
- yes 
- no 
- NAb 
 
467 
536 
45 
 
44.6 
51.1 
4.3 
 
a Cancer of unknown primary 
b Not available = unknown or not recorded 
c Gastro-Intestinal 
d Time between diagnosis of primary tumor and CM where applicable 
Table 2 Click here to access/download;Table;Brain mets_Table
2_10042019.docx
Table 3: Pre-treatment characteristics: Cerebral Metastasis 
Variable 
Total 
N 
1048 
% 
100.0 
Number of brain metastases 
- 1 
- 2 
- 3 
- 4 
- ≥ 5 
- LMDa 
- NAb 
 
541 
191 
93 
41 
162 
3 
17 
 
51.6 
18.2 
8.9 
3.9 
15.5 
< 0.3 
1.6 
Sentinel location of lesions 
- Frontal lobe 
- Temporal lobe 
- Parietal lobe 
- Occipital lobe 
- Cerebellum 
- Brainstem 
- Durally based 
- Other 
 
406 
79 
153 
96 
203 
22 
15 
49 
 
38.7 
7.5 
14.6 
9.2 
19.4 
2.1 
1.4 
4.7 
Size of sentinel metastasis 
- ≤ 30mm 
- > 30 mm 
- NAb 
 
637 
292 
119 
 
60.7 
27.9 
11.4 
Cranial imaging 
- CTHc 
- MRId Head 
- NAb 
 
635 
873 
13 
 
60.6 
83.3 
1.2 
Reason MRId not undertaken 
- Contraindicated 
- Patient unwilling 
- Indicated but not performed before MDTe 
- No clinical indication 
- NAb 
 
17 
3 
91 
48 
16 
 
9.7 
1.7 
52.0 
27.4 
9.1 
MRId sequences 
- Gadolinium contrast 
- Navigation sequence 
- DTIf 
- DWIg 
- Spectroscopy 
 
836 
378 
668 
66 
3 
 
95.8 
43.3 
76.5 
7.6 
0.3 
Prior brain surgery 
- yes 
- no 
- NAb 
 
154 
891 
3 
 
14.7 
85.0 
< 0.3 
 
a Leptomeningeal disease 
b Not available = unknown or not recorded 
c Computertomography of the head 
d Magnetic Resonance Imaging 
e Multi-disciplinary team meeting 
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f Diffusion tensor imaging 
g Diffusion-weighted imaging 
Table 4: Treatment recommendation 
 
Variable 
Total 
 
1CM 
541 
 
2-4CM 
325                 
 
≥5CM* 
165        
 
NA   
17 
 
N 
1048 
 
% 
100.0 
Specialist intervention 
- Surgical Resection alone 
- Surgical Resection + SRSa 
- Surgical Resection + SRS + cavity SRS 
- Surgical Resection + cavity SRS 
- Surgical Resection + chemo-/immunotherapy 
- Surgical Resection + WBRTb/local fx Rxc 
- Surgical Resection + CSFd diversion 
- SRS alone 
- SRS                       + WBRT/local fx Rx 
- SRS                       + chemo-/immunotherapy 
- Biopsy alone 
- Biopsy                   + SRS 
- CSF diversion 
- Clinic assessment to discuss Surgery/SRS 
365 
163 
8 
0 
21 
4 
12 
1 
126 
3 
14 
8 
0 
5 
0 
158 
31 
27 
2 
0 
2 
5 
2 
74 
1 
5 
3 
1 
2 
3 
28 
2 
2 
0 
0 
0 
1 
1 
18 
1 
1 
0 
0 
2 
0 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
551 
196 
37 
2 
21 
6 
18 
4 
218 
5 
20 
11 
1 
9 
3 
52.6 
18.7 
3.5 
<0.2 
2.0 
0.6 
1.7 
0.4 
20.8 
0.5 
1.9 
1.0 
<0.1 
0.9 
<0.3 
Non-Specialist treatment only 
- Chemotherapy 
- Immunotherapy 
- WBRT 
- Local fx Rx 
- Oncology treatment NOSe 
- Best supportive care 
- Re-imaging/surveillance 
- Referral to other speciality 
165 
8 
3 
20 
11 
13 
68 
29 
13 
147 
4 
2 
40 
4 
22 
62 
7 
6 
133 
6 
3 
54◊ 
1 
14 
50† 
3 
2 
1 
 
 
1 
 
 
 
 
 
447 
18 
8 
115 
16 
49 
180 
39 
22 
42.7 
1.7 
0.8 
11.0 
1.5 
4.7 
17.2 
3.7 
2.1 
No MDTf decision 
- NA 
- Indeterminate 
11 20 4 16 
 
 
51 
45 
6 
4.9 
4.3 
0.6 
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Delay in MDT decision 
- Yes 
- No 
- NAg 
     
195 
767 
86 
 
18.6 
73.2 
8.2 
Reason for delay (multiple) 
- Imaging not available 
- Insufficient information 
- Awaiting further investigations/results 
- Cancellation 
- Wrong MDT 
- Intentional delay 
- Assessment 
- Other 
     
102 
53 
27 
2 
15 
9 
8 
7 
 
52.3 
27.2 
13.8 
<0.2 
7.7 
4.6 
4.1 
3.6 
a Stereotactic radiosurgery  
b Whole brain radiation therapy 
c Local fractionated radiotherapy 
d Cerebrospinal fluid  
e Not otherwise specified (either WBRT or chemo-/immunotherapy or best supportive care) 
f Multi-disciplinary team meeting 
g Not available = unknown or not recorded 
* Includes patients with leptomeningeal disease (LMD) n=3 
◊ Includes n=1 with LMD 
† Includes n=2 with LMD 
Table 5: Factors that are associated with MDTa decision-making using univariate logistic regression 
Variable Comparison p-value 
Number of cerebral metastases single vs multiple <0.0001 
Age < 65years vs  ≥ 65 years <0.0001 
Karnfosky-Performance Status < 70 vs  ≥ 70 <0.0001 
Primary disease status controlled vs uncontrolled <0.0001 
Extracranial disease Brain metastasis only vs Brain and other metastases <0.0001 
Sentinel location Lobes/Cerebellum vs Brainstem/Basal ganglia/other =0.047 
Sentinel size ≤ 3cm vs > 3cm = 0.114 
Time interval < 2 years vs > 2 years = 0.925 
Prior brain surgery yes vs no = 0.720 
Histology of primary SCLCb vs TNBCc =0.009 
Preoperative neurological 
deficit 
yes (motor/speech/visual) vs no/missing =0.090 
Headache yes vs no = 0.100 
Delay in MDT decision yes vs no = 0.278 
MRId available yes vs no <0.0001 
 
a Multi-disciplinary team 
b Small cell lung cancer 
c Triple negative breast cancer 
d Magnetic Resonance Imaging 
Table 5 Click here to access/download;Table;Brain mets_Table
5_10042019.docx
Figure 1A Click here to access/download;Figure;Figure  1A.tif
Figure 1B Click here to access/download;Figure;Figure_1B.tif
Supplementary file 1 Click here to access/download;Supplementary file;Suppl Figure 1.TIF
Supplementary file 2 Click here to access/download;Supplementary file;Suppl Figure 2.TIF
Supplementary file 3 Click here to access/download;Supplementary file;Suppl Figure 3.TIF
Supplementary file 4 Click here to access/download;Supplementary file;Suppl Figure 4.tif
  
Supplementary Table and Figure legends
Click here to access/download
Hyperlinked Supplement
Supplementary Table and Figure legends.docx
